CTOs on the Move

Simulate

www.simulate.com

 
SIMULATE is an early-stage biotechnology company whose mission is to accelerate the world`s transition to sustainable nutrition. SIMULATE`s first product, NUGGS, is a chicken nugget simulation made from plant inputs. Since NUGGS launched in the Summer of 2019, NUGGS has evolved into the fastest-growing chicken nugget on the planet. SIMULATE is currently developing other products, some that will launch later in the year.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Simulate raised $50M on 06/08/2021

Similar Companies

Red Bull

The company behind the can: In 1987 Red Bull not only launched a completely new product, it created a whole new product category - the Energy Drink. Today, Red Bull employs more than 10,400 people, is available in more than 167 countries, and around 44 billion cans of Red Bull have been consumed. Red Bull has been giving wings to people and ideas for more than 27 years.

Oatly

It’s us, Oatly, the original Swedish oat drink company. We turn liquid oats into food and drinks with maximum nutritional value and minimal environmental impact

Neptune Technologies and Bioressources

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids ("PUFAs"). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune`s distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune`s products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune`s head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec. Neptune respectively holds approximately 49% of the participating and voting rights of Acasti and 96% of the voting rights of NeuroBio. Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBio respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti`s lead prescription drug candidate is CaPre(R), a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.